nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ORM1—saliva—nicotine dependence	0.0227	0.402	CbGeAlD
Fluoxetine—Enterocolitis—Varenicline—nicotine dependence	0.0203	0.0261	CcSEcCtD
Fluoxetine—Haematochezia—Varenicline—nicotine dependence	0.014	0.018	CcSEcCtD
Fluoxetine—Aphthous stomatitis—Varenicline—nicotine dependence	0.012	0.0154	CcSEcCtD
Fluoxetine—Myositis—Varenicline—nicotine dependence	0.0115	0.0147	CcSEcCtD
Fluoxetine—Peripheral vascular disorder—Varenicline—nicotine dependence	0.0115	0.0147	CcSEcCtD
Fluoxetine—Suicide—Varenicline—nicotine dependence	0.0109	0.0139	CcSEcCtD
Fluoxetine—Balance disorder—Varenicline—nicotine dependence	0.0103	0.0132	CcSEcCtD
Fluoxetine—Hostility—Varenicline—nicotine dependence	0.0102	0.0131	CcSEcCtD
Fluoxetine—Sexual dysfunction—Varenicline—nicotine dependence	0.0101	0.0129	CcSEcCtD
Fluoxetine—Osteoporosis—Varenicline—nicotine dependence	0.0101	0.0129	CcSEcCtD
Fluoxetine—Suicide attempt—Varenicline—nicotine dependence	0.00995	0.0127	CcSEcCtD
Fluoxetine—Gastric ulcer—Varenicline—nicotine dependence	0.00971	0.0124	CcSEcCtD
Fluoxetine—CYP2B6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00965	0.0592	CbGpPWpGaD
Fluoxetine—Completed suicide—Varenicline—nicotine dependence	0.0096	0.0123	CcSEcCtD
Fluoxetine—Libido increased—Varenicline—nicotine dependence	0.00928	0.0119	CcSEcCtD
Fluoxetine—Vaginal discharge—Varenicline—nicotine dependence	0.00928	0.0119	CcSEcCtD
Fluoxetine—Psoriasis—Varenicline—nicotine dependence	0.00898	0.0115	CcSEcCtD
Fluoxetine—Parosmia—Varenicline—nicotine dependence	0.0087	0.0112	CcSEcCtD
Fluoxetine—Menstrual disorder—Varenicline—nicotine dependence	0.00828	0.0106	CcSEcCtD
Fluoxetine—Paranoia—Varenicline—nicotine dependence	0.00828	0.0106	CcSEcCtD
Fluoxetine—Intestinal obstruction—Varenicline—nicotine dependence	0.00828	0.0106	CcSEcCtD
Fluoxetine—Haematemesis—Varenicline—nicotine dependence	0.00812	0.0104	CcSEcCtD
Fluoxetine—Suicidal ideation—Varenicline—nicotine dependence	0.00805	0.0103	CcSEcCtD
Fluoxetine—Thrombosis—Varenicline—nicotine dependence	0.00797	0.0102	CcSEcCtD
Fluoxetine—Delusion—Varenicline—nicotine dependence	0.00797	0.0102	CcSEcCtD
Fluoxetine—Hyperlipidaemia—Varenicline—nicotine dependence	0.00783	0.01	CcSEcCtD
Fluoxetine—Mania—Varenicline—nicotine dependence	0.00776	0.00994	CcSEcCtD
Fluoxetine—Menorrhagia—Varenicline—nicotine dependence	0.00763	0.00977	CcSEcCtD
Fluoxetine—CYP2B6—Fatty acids—CYP2A7—nicotine dependence	0.00753	0.0462	CbGpPWpGaD
Fluoxetine—Extrapyramidal disorder—Varenicline—nicotine dependence	0.0075	0.0096	CcSEcCtD
Fluoxetine—Scotoma—Varenicline—nicotine dependence	0.00743	0.00952	CcSEcCtD
Fluoxetine—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00729	0.0447	CbGpPWpGaD
Fluoxetine—Gingivitis—Varenicline—nicotine dependence	0.00719	0.00921	CcSEcCtD
Fluoxetine—Mydriasis—Varenicline—nicotine dependence	0.00708	0.00907	CcSEcCtD
Fluoxetine—Nephrolithiasis—Varenicline—nicotine dependence	0.00702	0.009	CcSEcCtD
Fluoxetine—Glycosuria—Varenicline—nicotine dependence	0.00697	0.00893	CcSEcCtD
Fluoxetine—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00671	0.0411	CbGpPWpGaD
Fluoxetine—Acne—Varenicline—nicotine dependence	0.00671	0.00859	CcSEcCtD
Fluoxetine—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00665	0.0408	CbGpPWpGaD
Fluoxetine—Disturbance in attention—Varenicline—nicotine dependence	0.00652	0.00835	CcSEcCtD
Fluoxetine—Aggression—Varenicline—nicotine dependence	0.00642	0.00823	CcSEcCtD
Fluoxetine—Accidental injury—Varenicline—nicotine dependence	0.00638	0.00817	CcSEcCtD
Fluoxetine—Ventricular extrasystoles—Varenicline—nicotine dependence	0.00625	0.00801	CcSEcCtD
Fluoxetine—Thinking abnormal—Varenicline—nicotine dependence	0.00617	0.0079	CcSEcCtD
Fluoxetine—Nocturia—Varenicline—nicotine dependence	0.00608	0.0078	CcSEcCtD
Fluoxetine—Leukocytosis—Varenicline—nicotine dependence	0.00601	0.0077	CcSEcCtD
Fluoxetine—CYP2B6—Xenobiotics—CYP2A7—nicotine dependence	0.00598	0.0367	CbGpPWpGaD
Fluoxetine—Dysarthria—Varenicline—nicotine dependence	0.00597	0.00765	CcSEcCtD
Fluoxetine—CYP3A5—Xenobiotics—CYP2A7—nicotine dependence	0.00585	0.0358	CbGpPWpGaD
Fluoxetine—Coordination abnormal—Varenicline—nicotine dependence	0.00575	0.00736	CcSEcCtD
Fluoxetine—Blood pressure increased—Varenicline—nicotine dependence	0.00564	0.00723	CcSEcCtD
Fluoxetine—Pulmonary embolism—Varenicline—nicotine dependence	0.00564	0.00723	CcSEcCtD
Fluoxetine—Abnormal dreams—Varenicline—nicotine dependence	0.00558	0.00715	CcSEcCtD
Fluoxetine—Eructation—Varenicline—nicotine dependence	0.00555	0.00711	CcSEcCtD
Fluoxetine—Hyperkalaemia—Varenicline—nicotine dependence	0.00555	0.00711	CcSEcCtD
Fluoxetine—Salivary hypersecretion—Varenicline—nicotine dependence	0.00548	0.00702	CcSEcCtD
Fluoxetine—Photophobia—Varenicline—nicotine dependence	0.0053	0.00679	CcSEcCtD
Fluoxetine—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00523	0.0321	CbGpPWpGaD
Fluoxetine—Dry eye—Varenicline—nicotine dependence	0.00521	0.00668	CcSEcCtD
Fluoxetine—Oesophagitis—Varenicline—nicotine dependence	0.00516	0.00661	CcSEcCtD
Fluoxetine—Urine output increased—Varenicline—nicotine dependence	0.0051	0.00654	CcSEcCtD
Fluoxetine—Mouth ulceration—Varenicline—nicotine dependence	0.0051	0.00654	CcSEcCtD
Fluoxetine—Hypertonia—Varenicline—nicotine dependence	0.00495	0.00634	CcSEcCtD
Fluoxetine—Mental disability—Varenicline—nicotine dependence	0.0049	0.00628	CcSEcCtD
Fluoxetine—Euphoric mood—Varenicline—nicotine dependence	0.00485	0.00621	CcSEcCtD
Fluoxetine—Lymphadenopathy—Varenicline—nicotine dependence	0.0048	0.00615	CcSEcCtD
Fluoxetine—Sleep disorder—Varenicline—nicotine dependence	0.00473	0.00606	CcSEcCtD
Fluoxetine—Diabetes mellitus—Varenicline—nicotine dependence	0.00471	0.00604	CcSEcCtD
Fluoxetine—Polyuria—Varenicline—nicotine dependence	0.00467	0.00598	CcSEcCtD
Fluoxetine—Deafness—Varenicline—nicotine dependence	0.00458	0.00587	CcSEcCtD
Fluoxetine—Eczema—Varenicline—nicotine dependence	0.00456	0.00584	CcSEcCtD
Fluoxetine—Eye pain—Varenicline—nicotine dependence	0.00454	0.00582	CcSEcCtD
Fluoxetine—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00452	0.0277	CbGpPWpGaD
Fluoxetine—Injury—Varenicline—nicotine dependence	0.00446	0.00571	CcSEcCtD
Fluoxetine—Libido decreased—Varenicline—nicotine dependence	0.00442	0.00566	CcSEcCtD
Fluoxetine—Hot flush—Varenicline—nicotine dependence	0.00438	0.00561	CcSEcCtD
Fluoxetine—Increased appetite—Varenicline—nicotine dependence	0.00436	0.00559	CcSEcCtD
Fluoxetine—Amnesia—Varenicline—nicotine dependence	0.00436	0.00559	CcSEcCtD
Fluoxetine—Menopausal symptoms—Varenicline—nicotine dependence	0.00434	0.00556	CcSEcCtD
Fluoxetine—Atrial fibrillation—Varenicline—nicotine dependence	0.00432	0.00554	CcSEcCtD
Fluoxetine—Thirst—Varenicline—nicotine dependence	0.0043	0.00552	CcSEcCtD
Fluoxetine—Arthritis—Varenicline—nicotine dependence	0.00422	0.0054	CcSEcCtD
Fluoxetine—Hypoglycaemia—Varenicline—nicotine dependence	0.0042	0.00538	CcSEcCtD
Fluoxetine—Cerebrovascular accident—Varenicline—nicotine dependence	0.00418	0.00536	CcSEcCtD
Fluoxetine—Lethargy—Varenicline—nicotine dependence	0.00418	0.00536	CcSEcCtD
Fluoxetine—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00416	0.0255	CbGpPWpGaD
Fluoxetine—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00412	0.0253	CbGpPWpGaD
Fluoxetine—Osteoarthritis—Varenicline—nicotine dependence	0.0041	0.00525	CcSEcCtD
Fluoxetine—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.0041	0.00525	CcSEcCtD
Fluoxetine—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00406	0.00521	CcSEcCtD
Fluoxetine—Migraine—Varenicline—nicotine dependence	0.00403	0.00517	CcSEcCtD
Fluoxetine—Affect lability—Varenicline—nicotine dependence	0.00403	0.00517	CcSEcCtD
Fluoxetine—Psychotic disorder—Varenicline—nicotine dependence	0.004	0.00513	CcSEcCtD
Fluoxetine—Irritability—Varenicline—nicotine dependence	0.00391	0.00501	CcSEcCtD
Fluoxetine—Urinary retention—Varenicline—nicotine dependence	0.0039	0.00499	CcSEcCtD
Fluoxetine—Mood swings—Varenicline—nicotine dependence	0.00388	0.00497	CcSEcCtD
Fluoxetine—Liver function test abnormal—Varenicline—nicotine dependence	0.00378	0.00485	CcSEcCtD
Fluoxetine—Dry skin—Varenicline—nicotine dependence	0.00376	0.00481	CcSEcCtD
Fluoxetine—Hypokalaemia—Varenicline—nicotine dependence	0.00373	0.00478	CcSEcCtD
Fluoxetine—Breast disorder—Varenicline—nicotine dependence	0.0037	0.00474	CcSEcCtD
Fluoxetine—Gastritis—Varenicline—nicotine dependence	0.00363	0.00465	CcSEcCtD
Fluoxetine—Abdominal distension—Varenicline—nicotine dependence	0.00356	0.00457	CcSEcCtD
Fluoxetine—Dysphagia—Varenicline—nicotine dependence	0.00354	0.00454	CcSEcCtD
Fluoxetine—Asthma—Varenicline—nicotine dependence	0.00354	0.00454	CcSEcCtD
Fluoxetine—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00352	0.0216	CbGpPWpGaD
Fluoxetine—Angina pectoris—Varenicline—nicotine dependence	0.00345	0.00442	CcSEcCtD
Fluoxetine—Bronchitis—Varenicline—nicotine dependence	0.00341	0.00436	CcSEcCtD
Fluoxetine—Pollakiuria—Varenicline—nicotine dependence	0.00327	0.00419	CcSEcCtD
Fluoxetine—Erectile dysfunction—Varenicline—nicotine dependence	0.00326	0.00418	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Varenicline—nicotine dependence	0.00323	0.00414	CcSEcCtD
Fluoxetine—Weight increased—Varenicline—nicotine dependence	0.00322	0.00413	CcSEcCtD
Fluoxetine—HTR2C—midbrain—nicotine dependence	0.00321	0.0569	CbGeAlD
Fluoxetine—Hyperglycaemia—Varenicline—nicotine dependence	0.00319	0.00409	CcSEcCtD
Fluoxetine—Depression—Varenicline—nicotine dependence	0.00315	0.00403	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00313	0.00401	CcSEcCtD
Fluoxetine—Acute coronary syndrome—Varenicline—nicotine dependence	0.00311	0.00399	CcSEcCtD
Fluoxetine—Myocardial infarction—Varenicline—nicotine dependence	0.00309	0.00397	CcSEcCtD
Fluoxetine—Stomatitis—Varenicline—nicotine dependence	0.00308	0.00394	CcSEcCtD
Fluoxetine—Conjunctivitis—Varenicline—nicotine dependence	0.00307	0.00393	CcSEcCtD
Fluoxetine—SLC6A4—midbrain—nicotine dependence	0.00304	0.054	CbGeAlD
Fluoxetine—SIGMAR1—midbrain—nicotine dependence	0.00302	0.0536	CbGeAlD
Fluoxetine—Epistaxis—Varenicline—nicotine dependence	0.00298	0.00382	CcSEcCtD
Fluoxetine—Sinusitis—Varenicline—nicotine dependence	0.00296	0.0038	CcSEcCtD
Fluoxetine—Bradycardia—Varenicline—nicotine dependence	0.00289	0.0037	CcSEcCtD
Fluoxetine—Hallucination—Varenicline—nicotine dependence	0.00282	0.00361	CcSEcCtD
Fluoxetine—Hypoaesthesia—Varenicline—nicotine dependence	0.00282	0.00361	CcSEcCtD
Fluoxetine—Oedema peripheral—Varenicline—nicotine dependence	0.00279	0.00358	CcSEcCtD
Fluoxetine—Visual impairment—Varenicline—nicotine dependence	0.00273	0.0035	CcSEcCtD
Fluoxetine—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00272	0.0167	CbGpPWpGaD
Fluoxetine—Erythema multiforme—Varenicline—nicotine dependence	0.00268	0.00343	CcSEcCtD
Fluoxetine—Tinnitus—Varenicline—nicotine dependence	0.00264	0.00339	CcSEcCtD
Fluoxetine—HTR2C—Monoamine GPCRs—DRD2—nicotine dependence	0.00256	0.0157	CbGpPWpGaD
Fluoxetine—Chills—Varenicline—nicotine dependence	0.00254	0.00326	CcSEcCtD
Fluoxetine—Arrhythmia—Varenicline—nicotine dependence	0.00253	0.00324	CcSEcCtD
Fluoxetine—CYP2B6—cardiovascular system—nicotine dependence	0.00253	0.0448	CbGeAlD
Fluoxetine—CYP2C9—cardiovascular system—nicotine dependence	0.0025	0.0444	CbGeAlD
Fluoxetine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00248	0.0152	CbGpPWpGaD
Fluoxetine—Mental disorder—Varenicline—nicotine dependence	0.00248	0.00318	CcSEcCtD
Fluoxetine—Malnutrition—Varenicline—nicotine dependence	0.00247	0.00316	CcSEcCtD
Fluoxetine—CYP2B6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00245	0.015	CbGpPWpGaD
Fluoxetine—Flatulence—Varenicline—nicotine dependence	0.00243	0.00312	CcSEcCtD
Fluoxetine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00243	0.0149	CbGpPWpGaD
Fluoxetine—Dysgeusia—Varenicline—nicotine dependence	0.00242	0.0031	CcSEcCtD
Fluoxetine—CYP3A5—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0024	0.0147	CbGpPWpGaD
Fluoxetine—Back pain—Varenicline—nicotine dependence	0.00239	0.00306	CcSEcCtD
Fluoxetine—Muscle spasms—Varenicline—nicotine dependence	0.00237	0.00304	CcSEcCtD
Fluoxetine—Tremor—Varenicline—nicotine dependence	0.00231	0.00296	CcSEcCtD
Fluoxetine—Ill-defined disorder—Varenicline—nicotine dependence	0.00229	0.00293	CcSEcCtD
Fluoxetine—Anaemia—Varenicline—nicotine dependence	0.00228	0.00292	CcSEcCtD
Fluoxetine—Agitation—Varenicline—nicotine dependence	0.00227	0.00291	CcSEcCtD
Fluoxetine—Angioedema—Varenicline—nicotine dependence	0.00225	0.00289	CcSEcCtD
Fluoxetine—Malaise—Varenicline—nicotine dependence	0.00222	0.00285	CcSEcCtD
Fluoxetine—HTR2A—Monoamine GPCRs—DRD2—nicotine dependence	0.00222	0.0136	CbGpPWpGaD
Fluoxetine—Vertigo—Varenicline—nicotine dependence	0.00222	0.00284	CcSEcCtD
Fluoxetine—Syncope—Varenicline—nicotine dependence	0.00221	0.00284	CcSEcCtD
Fluoxetine—Palpitations—Varenicline—nicotine dependence	0.00218	0.00279	CcSEcCtD
Fluoxetine—Loss of consciousness—Varenicline—nicotine dependence	0.00217	0.00278	CcSEcCtD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00216	0.0132	CbGpPWpGaD
Fluoxetine—Cough—Varenicline—nicotine dependence	0.00215	0.00276	CcSEcCtD
Fluoxetine—HTR2C—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00215	0.0132	CbGpPWpGaD
Fluoxetine—Convulsion—Varenicline—nicotine dependence	0.00214	0.00274	CcSEcCtD
Fluoxetine—Hypertension—Varenicline—nicotine dependence	0.00213	0.00273	CcSEcCtD
Fluoxetine—Arthralgia—Varenicline—nicotine dependence	0.0021	0.00269	CcSEcCtD
Fluoxetine—Chest pain—Varenicline—nicotine dependence	0.0021	0.00269	CcSEcCtD
Fluoxetine—Myalgia—Varenicline—nicotine dependence	0.0021	0.00269	CcSEcCtD
Fluoxetine—Anxiety—Varenicline—nicotine dependence	0.00209	0.00268	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00209	0.00267	CcSEcCtD
Fluoxetine—Discomfort—Varenicline—nicotine dependence	0.00208	0.00266	CcSEcCtD
Fluoxetine—HTR2A—cardiovascular system—nicotine dependence	0.00206	0.0366	CbGeAlD
Fluoxetine—Dry mouth—Varenicline—nicotine dependence	0.00205	0.00263	CcSEcCtD
Fluoxetine—HTR2C—brain—nicotine dependence	0.00202	0.0358	CbGeAlD
Fluoxetine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00201	0.0123	CbGpPWpGaD
Fluoxetine—Infection—Varenicline—nicotine dependence	0.002	0.00256	CcSEcCtD
Fluoxetine—Shock—Varenicline—nicotine dependence	0.00198	0.00254	CcSEcCtD
Fluoxetine—Thrombocytopenia—Varenicline—nicotine dependence	0.00197	0.00253	CcSEcCtD
Fluoxetine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00197	0.0121	CbGpPWpGaD
Fluoxetine—ALB—brain—nicotine dependence	0.00197	0.0349	CbGeAlD
Fluoxetine—Tachycardia—Varenicline—nicotine dependence	0.00197	0.00252	CcSEcCtD
Fluoxetine—Skin disorder—Varenicline—nicotine dependence	0.00196	0.00251	CcSEcCtD
Fluoxetine—Hyperhidrosis—Varenicline—nicotine dependence	0.00195	0.00249	CcSEcCtD
Fluoxetine—Anorexia—Varenicline—nicotine dependence	0.00192	0.00246	CcSEcCtD
Fluoxetine—SLC6A4—brain—nicotine dependence	0.00191	0.0339	CbGeAlD
Fluoxetine—SIGMAR1—brain—nicotine dependence	0.0019	0.0337	CbGeAlD
Fluoxetine—Hypotension—Varenicline—nicotine dependence	0.00188	0.00241	CcSEcCtD
Fluoxetine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00188	0.0115	CbGpPWpGaD
Fluoxetine—HTR2A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00187	0.0114	CbGpPWpGaD
Fluoxetine—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00185	0.0114	CbGpPWpGaD
Fluoxetine—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00183	0.00235	CcSEcCtD
Fluoxetine—Insomnia—Varenicline—nicotine dependence	0.00182	0.00233	CcSEcCtD
Fluoxetine—Dyspnoea—Varenicline—nicotine dependence	0.0018	0.0023	CcSEcCtD
Fluoxetine—Somnolence—Varenicline—nicotine dependence	0.00179	0.00229	CcSEcCtD
Fluoxetine—Dyspepsia—Varenicline—nicotine dependence	0.00177	0.00227	CcSEcCtD
Fluoxetine—Decreased appetite—Varenicline—nicotine dependence	0.00175	0.00224	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00174	0.00223	CcSEcCtD
Fluoxetine—Fatigue—Varenicline—nicotine dependence	0.00174	0.00222	CcSEcCtD
Fluoxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00173	0.0106	CbGpPWpGaD
Fluoxetine—Constipation—Varenicline—nicotine dependence	0.00172	0.00221	CcSEcCtD
Fluoxetine—Pain—Varenicline—nicotine dependence	0.00172	0.00221	CcSEcCtD
Fluoxetine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00171	0.0105	CbGpPWpGaD
Fluoxetine—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0017	0.0104	CbGpPWpGaD
Fluoxetine—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00169	0.0104	CbGpPWpGaD
Fluoxetine—SLC6A2—brain—nicotine dependence	0.00168	0.0299	CbGeAlD
Fluoxetine—Feeling abnormal—Varenicline—nicotine dependence	0.00166	0.00213	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Varenicline—nicotine dependence	0.00165	0.00211	CcSEcCtD
Fluoxetine—HTR2A—midbrain—nicotine dependence	0.00161	0.0286	CbGeAlD
Fluoxetine—Urticaria—Varenicline—nicotine dependence	0.0016	0.00205	CcSEcCtD
Fluoxetine—Abdominal pain—Varenicline—nicotine dependence	0.00159	0.00204	CcSEcCtD
Fluoxetine—Body temperature increased—Varenicline—nicotine dependence	0.00159	0.00204	CcSEcCtD
Fluoxetine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00152	0.00933	CbGpPWpGaD
Fluoxetine—Hypersensitivity—Varenicline—nicotine dependence	0.00148	0.0019	CcSEcCtD
Fluoxetine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00146	0.00896	CbGpPWpGaD
Fluoxetine—Asthenia—Varenicline—nicotine dependence	0.00144	0.00185	CcSEcCtD
Fluoxetine—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00144	0.00885	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00144	0.00883	CbGpPWpGaD
Fluoxetine—Pruritus—Varenicline—nicotine dependence	0.00142	0.00183	CcSEcCtD
Fluoxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0014	0.00858	CbGpPWpGaD
Fluoxetine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00139	0.0085	CbGpPWpGaD
Fluoxetine—Diarrhoea—Varenicline—nicotine dependence	0.00138	0.00177	CcSEcCtD
Fluoxetine—ABCB1—cardiovascular system—nicotine dependence	0.00135	0.024	CbGeAlD
Fluoxetine—Dizziness—Varenicline—nicotine dependence	0.00133	0.00171	CcSEcCtD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00131	0.00802	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.0013	0.00797	CbGpPWpGaD
Fluoxetine—Vomiting—Varenicline—nicotine dependence	0.00128	0.00164	CcSEcCtD
Fluoxetine—Rash—Varenicline—nicotine dependence	0.00127	0.00163	CcSEcCtD
Fluoxetine—Dermatitis—Varenicline—nicotine dependence	0.00127	0.00163	CcSEcCtD
Fluoxetine—Headache—Varenicline—nicotine dependence	0.00126	0.00162	CcSEcCtD
Fluoxetine—CYP2B6—brain—nicotine dependence	0.00124	0.022	CbGeAlD
Fluoxetine—Nausea—Varenicline—nicotine dependence	0.0012	0.00153	CcSEcCtD
Fluoxetine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00119	0.00727	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00118	0.00721	CbGpPWpGaD
Fluoxetine—CYP2B6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00113	0.00696	CbGpPWpGaD
Fluoxetine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00113	0.00692	CbGpPWpGaD
Fluoxetine—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00111	0.00683	CbGpPWpGaD
Fluoxetine—CYP3A5—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00111	0.0068	CbGpPWpGaD
Fluoxetine—CYP2B6—Biological oxidations—CYP2A7—nicotine dependence	0.00107	0.00656	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—TAS2R16—nicotine dependence	0.00106	0.00648	CbGpPWpGaD
Fluoxetine—ABCB1—midbrain—nicotine dependence	0.00106	0.0187	CbGeAlD
Fluoxetine—CYP2B6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00106	0.00647	CbGpPWpGaD
Fluoxetine—CYP3A5—Biological oxidations—CYP2A7—nicotine dependence	0.00105	0.00641	CbGpPWpGaD
Fluoxetine—CYP3A5—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00103	0.00632	CbGpPWpGaD
Fluoxetine—HTR2A—brain—nicotine dependence	0.00101	0.0179	CbGeAlD
Fluoxetine—CYP2D6—brain—nicotine dependence	0.000922	0.0163	CbGeAlD
Fluoxetine—HTR2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.000918	0.00563	CbGpPWpGaD
Fluoxetine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000915	0.00561	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—DRD2—nicotine dependence	0.00087	0.00533	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.000868	0.00532	CbGpPWpGaD
Fluoxetine—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000858	0.00526	CbGpPWpGaD
Fluoxetine—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.000808	0.00495	CbGpPWpGaD
Fluoxetine—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000797	0.00489	CbGpPWpGaD
Fluoxetine—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000789	0.00483	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000788	0.00483	CbGpPWpGaD
Fluoxetine—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000782	0.00479	CbGpPWpGaD
Fluoxetine—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000744	0.00456	CbGpPWpGaD
Fluoxetine—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.000737	0.00452	CbGpPWpGaD
Fluoxetine—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000733	0.00449	CbGpPWpGaD
Fluoxetine—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000727	0.00446	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000683	0.00419	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000668	0.0041	CbGpPWpGaD
Fluoxetine—ABCB1—brain—nicotine dependence	0.000663	0.0118	CbGeAlD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000654	0.00401	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.00063	0.00386	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000621	0.00381	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000598	0.00366	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000593	0.00364	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000585	0.00359	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—TAS2R16—nicotine dependence	0.000543	0.00333	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000519	0.00318	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000516	0.00316	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000508	0.00311	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000494	0.00303	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000486	0.00298	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000479	0.00294	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000471	0.00289	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—FGD1—nicotine dependence	0.000469	0.00287	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—OPRM1—nicotine dependence	0.000446	0.00273	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000429	0.00263	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—FGD1—nicotine dependence	0.000426	0.00261	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000423	0.00259	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—FGD1—nicotine dependence	0.000407	0.0025	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000387	0.00237	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—FGD1—nicotine dependence	0.00037	0.00227	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000367	0.00225	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000329	0.00202	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—DRD2—nicotine dependence	0.000322	0.00197	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TAS2R16—nicotine dependence	0.000321	0.00196	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000288	0.00177	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—DRD2—nicotine dependence	0.00028	0.00171	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TAS2R16—nicotine dependence	0.000278	0.00171	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—OPRM1—nicotine dependence	0.000252	0.00154	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—FGD1—nicotine dependence	0.000252	0.00154	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—OPRM1—nicotine dependence	0.000229	0.0014	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—AKR1B10—nicotine dependence	0.000222	0.00136	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000219	0.00134	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FGD1—nicotine dependence	0.000218	0.00134	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—OPRM1—nicotine dependence	0.000199	0.00122	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—AKR1B10—nicotine dependence	0.000193	0.00118	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP2A7—nicotine dependence	0.000183	0.00112	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—DRD2—nicotine dependence	0.000182	0.00112	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP2A7—nicotine dependence	0.000179	0.0011	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—DRD2—nicotine dependence	0.000165	0.00101	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—DRD2—nicotine dependence	0.000158	0.000969	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—WASF2—nicotine dependence	0.000157	0.000959	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP2A7—nicotine dependence	0.000154	0.000944	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—WASF1—nicotine dependence	0.00015	0.00092	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—DRD2—nicotine dependence	0.000144	0.00088	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000138	0.000847	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—WASF2—nicotine dependence	0.000136	0.000833	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—OPRM1—nicotine dependence	0.000135	0.000828	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000135	0.000827	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—WASF1—nicotine dependence	0.00013	0.000799	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000127	0.000779	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000126	0.000773	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—OPRM1—nicotine dependence	0.000117	0.000719	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000108	0.00066	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—DRD2—nicotine dependence	9.77e-05	0.000599	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—DRD2—nicotine dependence	8.48e-05	0.00052	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2A7—nicotine dependence	8.31e-05	0.00051	CbGpPWpGaD
